1. Home
  2. GSBD vs NVCR Comparison

GSBD vs NVCR Comparison

Compare GSBD & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GSBD
  • NVCR
  • Stock Information
  • Founded
  • GSBD 2012
  • NVCR 2000
  • Country
  • GSBD United States
  • NVCR Jersey
  • Employees
  • GSBD N/A
  • NVCR N/A
  • Industry
  • GSBD Finance: Consumer Services
  • NVCR Medical/Dental Instruments
  • Sector
  • GSBD Finance
  • NVCR Health Care
  • Exchange
  • GSBD Nasdaq
  • NVCR Nasdaq
  • Market Cap
  • GSBD 1.7B
  • NVCR 1.8B
  • IPO Year
  • GSBD N/A
  • NVCR 2015
  • Fundamental
  • Price
  • GSBD $12.77
  • NVCR $16.11
  • Analyst Decision
  • GSBD Hold
  • NVCR Buy
  • Analyst Count
  • GSBD 3
  • NVCR 5
  • Target Price
  • GSBD $13.67
  • NVCR $26.60
  • AVG Volume (30 Days)
  • GSBD 790.5K
  • NVCR 955.2K
  • Earning Date
  • GSBD 11-07-2024
  • NVCR 10-30-2024
  • Dividend Yield
  • GSBD 14.10%
  • NVCR N/A
  • EPS Growth
  • GSBD N/A
  • NVCR N/A
  • EPS
  • GSBD 0.67
  • NVCR N/A
  • Revenue
  • GSBD $445,944,000.00
  • NVCR $577,738,000.00
  • Revenue This Year
  • GSBD $0.42
  • NVCR $19.13
  • Revenue Next Year
  • GSBD N/A
  • NVCR $5.33
  • P/E Ratio
  • GSBD $18.98
  • NVCR N/A
  • Revenue Growth
  • GSBD N/A
  • NVCR 14.63
  • 52 Week Low
  • GSBD $12.67
  • NVCR $11.29
  • 52 Week High
  • GSBD $15.94
  • NVCR $24.74
  • Technical
  • Relative Strength Index (RSI)
  • GSBD 33.36
  • NVCR 44.79
  • Support Level
  • GSBD $12.68
  • NVCR $17.28
  • Resistance Level
  • GSBD $12.99
  • NVCR $18.38
  • Average True Range (ATR)
  • GSBD 0.24
  • NVCR 1.12
  • MACD
  • GSBD -0.03
  • NVCR -0.04
  • Stochastic Oscillator
  • GSBD 9.60
  • NVCR 28.29

About GSBD Goldman Sachs BDC Inc.

Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests primarily in U.S. middle-market companies such as banks and the public debt markets. The company's origination strategy focuses on leading the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.

About NVCR NovoCure Limited

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Share on Social Networks: